Role and mechanism of programmed death‑ligand 1 in hypoxia‑induced liver cancer immune escape (Review)
- Authors:
- Qingxian Wen
- Tao Han
- Zijian Wang
- Shulong Jiang
-
Affiliations: Clinical Medical Laboratory Center, Jining No. 1 People's Hospital, Jining Medical University, Jining, Shandong 272000, P.R. China, Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Department of Radiation Oncology, Shandong Cancer Hospital, Shandong First Medical University, Jinan, Shandong 250000, P.R. China - Published online on: February 5, 2020 https://doi.org/10.3892/ol.2020.11369
- Pages: 2595-2601
-
Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han C, Jiang Y, Wang Z and Wang H: Natural killer cells involved in tumour immune escape of hepatocellular carcinomar. Int Immunopharmacol. 73:10–16. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Y, Xiang Y, Sheng J, Zhang D, Yao X, Yang Y and Zhang X: Immunotherapy for hepatocellular carcinoma: Current advances and future expectations. J Immunol Res. 2018:87409762018. View Article : Google Scholar : PubMed/NCBI | |
|
Harding JJ, El Dika I and Abou-Alfa GK: Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 122:367–377. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Najafi M, Farhood B and Mortezaee K: Contribution of regulatory T cells to cancer: A review. J Cell Physiol. 234:7983–7993. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shergold AL, Millar R and Nibbs RJB: Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol Res. 145:1042582019. View Article : Google Scholar : PubMed/NCBI | |
|
Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A and Lambris JD: Complementing the cancer-immunity cycle. Front Immunol. 10:7742019. View Article : Google Scholar : PubMed/NCBI | |
|
Prestipino A and Zeiser R: Clinical implications of tumor-intrinsic mechanisms regulating PD-L1. Sci Transl Med. 11(pii): eaav48102019. View Article : Google Scholar : PubMed/NCBI | |
|
Iñarrairaegui M, Melero I and Sangro B: Immunotherapy of hepatocellular carcinoma: Facts and hopes. Clin Cancer Res. 24:1518–1524. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T and Konishi I: PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int J Clin Oncol. 21:462–473. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mocan T, Sparchez Z, Craciun R, Bora CN and Leucuta DC: Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: Prognostic and therapeutic perspectives. Clin Transl Oncol. 21:702–712. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ho CM, Chen HL, Hu RH and Lee PH: Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective. Ther Adv Med Oncol. 11:17588359198434632019. View Article : Google Scholar : PubMed/NCBI | |
|
Barsoum IB, Smallwood CA, Siemens DR and Graham CH: A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74:665–674. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Jiang CC, Jin L and Zhang XD: Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guo R, Li Y, Wang Z, Bai H, Duan J, Wang S, Wang L and Wang J: Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Cancer Sci. 110:1665–1675. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L and Coukos G: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 475:226–230. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Terry S, Buart S and Chouaib S: Hypoxic stress-induced tumor and immune plasticity, suppression, and impact on tumor heterogeneity. Front Immunol. 8:16252017. View Article : Google Scholar : PubMed/NCBI | |
|
Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim Y, et al: Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74:24–30. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Labiano S, Palazon A and Melero I: Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol. 42:378–386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Reig M, Boix L, Mariño Z, Torres F, Forns X and Bruix J: Liver cancer emergence associated with antiviral treatment: An immune surveillance failure? Semin Liver Dis. 37:109–118. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, et al: Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 59:1415–1426. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, et al: HCC Immune surveillance and antiviral therapy of hepatitis C virus infection. Liver Cancer. 8:41–65. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M: Systemic therapy for hepatocellular carcinoma: Latest advances. Cancers (Basel). 10(pii): E4122018. View Article : Google Scholar : PubMed/NCBI | |
|
Sahin B: Enlighting the shadow for advanced hepatocellular carcinoma: Immunotherapy with immune checkpoint inhibitors. J Gastrointest Cancer. 48:288–290. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Waidmann O: Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 18:905–910. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Farhood B, Najafi M and Mortezaee K: CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kosti P, Maher J and Arnold JN: Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 9:11042018. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L and Zhang X: Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine. 56:231–238. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lian S, Xie R, Ye Y, Xie X, Li S, Lu Y, Li B, Cheng Y, Katanaev VL and Jia L: Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 42:281–295. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Mezzadra R and Schumacher TN: Regulation and function of the PD-L1 checkpoint. Immunity. 48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR and Bleackley RC: Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol. 20:3781–3794. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sanmamed MF and Chen L: Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 20:256–261. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J and Kuang DM: Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 41:2314–2322. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Andersen MH: The balance players of the adaptive immune system. Cancer Res. 78:1379–1382. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Galdiero MR, Garlanda C, Jaillon S, Marone G and Mantovani A: Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 228:1404–1412. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell DJ and Koch MA: Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 11:119–130. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Bakthavatsalam R, Meng Z, Li Z, Li W, Perkins JD and Reyes J: PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice. Transplant Proc. 45:1853–1855. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Beswick EJ, Pinchuk IV, Das S, Powell DW and Reyes VE: Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect Immun. 75:4334–4341. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ding Q, Lu L, Zhou X, Zhou Y and Chou KY: Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. J Leukoc Biol. 90:77–86. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Geng L, Deng J, Jiang G, Song P, Wang Z, Jiang Z, Zhang M and Zheng S: B7-H1 up-regulated expression in human hepatocellular carcinoma tissue: Correlation with tumor interleukin-10 levels. Hepatogastroenterology. 58:960–964. 2011.PubMed/NCBI | |
|
Sormendi S and Wielockx B: Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Front Immunol. 9:402018. View Article : Google Scholar : PubMed/NCBI | |
|
Deng J, Li J, Sarde A, Lines JL, Lee YC, Qian DC, Pechenick DA, Manivanh R, Le Mercier I, Lowrey CH, et al: Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol Res. 7:1079–1090. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi Y, Yokota A, Harada H and Huang G: Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci. 110:1510–1517. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chouaib S, Umansky V and Kieda C: The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. Contemp Oncol (Pozn). 22:7–13. 2018.PubMed/NCBI | |
|
Guo X, Xue H, Shao Q, Wang J, Guo X, Chen X, Zhang J, Xu S, Li T, Zhang P, et al: Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget. 7:80521–80542. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vaupel P and Multhoff G: Hypoxia-/HIF-1α-driven factors of the tumor microenvironment impeding antitumor immune responses and promoting malignant progression. Adv Exp Med Biol. 1072:171–175. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar V and Gabrilovich DI: Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 143:512–519. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez PC, Ochoa AC and Al-Khami AA: Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front Immunol. 8:932017. View Article : Google Scholar : PubMed/NCBI | |
|
Munder M, Choi BS, Rogers M and Kropf P: L-arginine deprivation impairs Leishmania major-specific T-cell responses. Eur J Immunol. 39:2161–2172. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 5:641–654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hu CE, Gan J, Zhang RD, Cheng YR and Huang GJ: Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 46:156–164. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF and Korangy F: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 50:799–807. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK and Hellerbrand C: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, Zhou J, Li YW and Tang ZY: Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 131:498–510. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Soni S and Padwad YS: HIF-1 in cancer therapy: Two decade long story of a transcription factor. Acta Oncol. 56:503–515. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Jiang L and Zhong T: The role of HIF-1α in chemo-/radioresistant tumors. Onco Targets Ther. 11:3003–3011. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Petrova V, Annicchiarico-Petruzzelli M, Melino G and Amelio I: The hypoxic tumour microenvironment. Oncogenesis. 7:102018. View Article : Google Scholar : PubMed/NCBI | |
|
Günter J, Ruiz-Serrano A, Pickel C, Wenger RH and Scholz CC: The functional interplay between the HIF pathway and the ubiquitin system-more than a one-way road. Exp Cell Res. 356:152–159. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rabinovich GA, Gabrilovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bian X, Xiao YT, Wu T, Yao M, Du L, Ren S and Wang J: Microvesicles and chemokines in tumor microenvironment: Mediators of intercellular communications in tumor progression. Mol Cancer. 18:502019. View Article : Google Scholar : PubMed/NCBI | |
|
Gun SY, Lee SWL, Sieow JL and Wong SC: Targeting immune cells for cancer therapy. Redox Biol. 25:1011742019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Shen Y, Wang S, Shen Q and Zhou X: The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 415:117–128. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huynh J, Chand A, Gough D and Ernst M: Therapeutically exploiting STAT3 activity in cancer-using tissue repair as a road map. Nat Rev Cancer. 19:82–96. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Loh CY, Arya A, Naema AF, Wong WF, Sethi G and Looi CY: Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: Functions and therapeutic implication. Front Oncol. 9:482019. View Article : Google Scholar : PubMed/NCBI | |
|
Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C and Zazzeroni F: Cancer secretome and inflammation: The bright and the dark sides of NF-κB. Semin Cell Dev Biol. 78:51–61. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N and Taketomi A: Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kunnumakkara AB, Sailo BL, Banik K, Harsha C, Prasad S, Gupta SC, Bharti AC and Aggarwal BB: Chronic diseases, inflammation, and spices: How are they linked? J Transl Med. 16:142018. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Y, Mao R and Yang J: NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 4:176–185. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao P, Niu N, Wei T, Tozawa H, Chen X, Zhang C, Zhang J, Wada Y, Kapron CM and Liu J: The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget. 8:69139–69161. 2017.PubMed/NCBI | |
|
Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N and Russo A: miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 224:242–249. 2010.PubMed/NCBI | |
|
Van Welden S, Selfridge AC and Hindryckx P: Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 14:596–611. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T and Gorlach A: Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell. 18:4691–4697. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L and Shi Y: Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother. 61:101–108. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, et al: EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 5:12189–12202. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, Dalpke AH and Heeg K: PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol. 41:413–424. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Wen Q, Zhao Y, Gao Q and Bai Y: NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One. 8:e616022013. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M: Immuno-oncology in hepatocellular carcinoma: 2017 update. Oncology. 93 (Suppl 1):S147–S159. 2017. View Article : Google Scholar | |
|
Lin D and Wu J: Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. World J Gastroenterol. 21:12171–12178. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Fu Z, Zhou S, Gong J, Liu CA, Qiao Z and Li S: HIF-1α and HIF-2α: Siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation. PLoS One. 9:e889132014. View Article : Google Scholar : PubMed/NCBI | |
|
Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, et al: Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology. 57:1847–1857. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW and Sun X: Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci. 99:2055–2061. 2008.PubMed/NCBI | |
|
Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone GM, Pricl S and Catapano CV: Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol. 9:1194–1206. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ciombor KK, Feng Y, Benson AB III, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, et al: Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): A trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 32:1017–1027. 2014. View Article : Google Scholar : PubMed/NCBI |
